Citius Pharmaceuticals, Inc. announced completion of the acquisition of Leonard-Meron Biosciences, Inc. Prior to the acquisition, Mr. Leonard Mazur was the Chief Executive Officer and Chairman of the Board of Directors of Citius and a principal stockholder of LMB; and, Mr. Myron Holubiak was the President and Chief Executive Officer of LMB, a significant stockholder of LMB, and a director of Citius. Pursuant to the acquisition, Mr. Holubiak assumed the role of President and Chief Executive Officer of Citius and will continue as a director of Citius, and Mr. Mazur will remain as the Chairman of the Board of Citius.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6319 USD | -4.26% | -13.44% | -16.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.47% | 11Cr | |
+54.05% | 5.87TCr | |
-2.02% | 4.13TCr | |
+36.95% | 3.92TCr | |
-10.22% | 2.74TCr | |
+13.42% | 2.65TCr | |
-21.60% | 1.9TCr | |
+2.89% | 1.25TCr | |
+22.40% | 1.19TCr | |
+27.49% | 1.21TCr |
- Stock Market
- Equities
- CTXR Stock
- News Citius Pharmaceuticals, Inc.
- Citius Pharmaceuticals, Inc. Announces Management Changes